FDA Officially Ranks Condoms for Anal and Vaginal Use as 'Class II' Gadgets
Published Date: 5/8/2026
Rule
Summary
The FDA is officially classifying external condoms for anal or vaginal sex as Class II devices, meaning they have special safety rules but aren’t super strict. This change helps make sure condoms are safe and effective while making it easier for new, innovative products to reach you. The new rules took effect on May 8, 2026, and could speed up how quickly better condoms hit the market without extra costs.
Analyzed Economic Effects
4 provisions identified: 2 benefits, 2 costs, 0 mixed.
Condoms Reclassified to Class II
The FDA has officially classified external condoms for anal or vaginal intercourse as Class II (special controls). FDA says this classification provides a reasonable assurance of safety and effectiveness and will enhance patient access to innovative condom products by reducing regulatory burdens; the order is effective May 8, 2026 (classification applicable February 23, 2022).
New Testing and Labeling Rules for Makers
Manufacturers must meet new special controls: clinical acute failure modes studies for total and individual failure rates; non‑clinical performance testing including mechanical/material integrity and (for non‑latex materials) viral penetration testing; biocompatibility evaluation; shelf‑life performance and package integrity data; and specific labeling elements. These controls are codified at 21 CFR 884.5305 and apply to devices classified as external condoms for anal or vaginal intercourse.
Premarket 510(k) Notification Required
FDA states that external condoms for anal or vaginal intercourse are subject to premarket notification under section 510(k) of the FD&C Act and that it has not determined these devices should be exempt under section 510(m). Sponsors must therefore submit a 510(k) to market these devices unless FDA later exempts them.
Labels Must Give Clear Safety & Effectiveness Info
Required labeling must include (if indicated for vaginal intercourse) a contraceptive effectiveness table comparing typical and perfect use pregnancy rates; statements on lubricant compatibility; statements of adverse events (including infection, pregnancy, tissue reaction, mechanical injury, improper use); an expiration date; STI protection specifics; a statement that risks are not eliminated; a warning about failure during anal intercourse if adequate lubricant is not used; a warning that the device is single‑use; and a precaution about allergy risk.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10321 — Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Safety and Effectiveness of MFLUSIVA (Influenza Vaccine, mRNA) Manufactured by Moderna TX Inc.
The FDA is holding a public meeting on June 18, 2026, to talk about the safety and effectiveness of MFLUSIVA, a new flu vaccine made by Moderna. Anyone can watch online and share their thoughts before June 17. This is a big deal for people who get flu shots and could affect how this vaccine is used and approved.
2026-10295 — M11 Clinical Electronic Structured Harmonised Protocol (CeSHarP); International Council for Harmonisation; Guidance for Industry; Availability
The FDA just released a new, easy-to-use digital guide called M11 CeSHarP to help everyone involved in clinical trials share and review study plans faster and clearer. This affects drug companies, researchers, and regulators worldwide by setting a global standard for how trial info is written and shared electronically. The new rules kick in now, aiming to save time and reduce confusion, with no direct cost but big efficiency gains.
2026-10277 — Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
The FDA just released new draft guides to help drug makers design studies proving their generic drugs work like the originals. If you’re in the drug business, now’s your chance to share feedback by July 21, 2026, before these guides become final. These updates aim to speed up drug approvals, potentially saving time and money for companies and patients alike!
2026-10284 — Protein Efficiency Ratio Rat Bioassay Studies To Demonstrate That a New Infant Formula Supports the Quality Factor of Sufficient Biological Quality of Protein; Guidance for Industry; Availability
The FDA just released new guidance to help baby formula makers prove their products have good-quality protein using special rat studies. This update affects formula manufacturers and labs, making it easier and clearer to show their formulas meet nutrition standards. The guidance is effective now, helping companies avoid costly mistakes and speed up getting new formulas to market.
2026-10268 — Notice of Decision Not To Designate Hepatitis Delta Virus Diseases as an Addition to the Current List of Tropical Diseases in the Federal Food, Drug, and Cosmetic Act
The FDA decided not to add Hepatitis Delta Virus (HDV) to the list of tropical diseases because it doesn’t fully meet the rules about market size and who it affects. This means drug makers won’t get special priority review vouchers for HDV treatments right now. People working on HDV drugs should keep an eye out for future updates but won’t see changes or new incentives immediately.
2026-10190 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Patent Term Restoration; Due Diligence Petitions; Filing, Format, and Content of Petitions
The FDA is updating how companies ask for extra patent time when their new drugs or devices take a while to get approved. This affects drug and medical device makers who want to protect their inventions longer. Comments on these changes are open until June 22, 2026, and the update aims to keep the process clear without adding extra costs or delays.
Previous / Next Documents
Previous: 2026-09148 — Implementation of the Administrative False Claims Act; Correction
The Federal Labor Relations Authority fixed a few wording mistakes in its new rules for the Administrative False Claims Act, which helps catch and stop false claims against the government. These corrections make the rules clearer and officially take effect on May 26, 2026. If you work with government claims or legal procedures, these updates keep things running smoothly without changing any costs or deadlines.
Next: 2026-09155 — Changes to National Firearms Act Tax Remittance Provisions
Starting June 10, 2026, the ATF is updating its rules to match new laws that lower the tax rates on certain National Firearms Act (NFA) guns. This means folks who deal with these firearms will pay less tax when registering or transferring them. The changes keep the rules clear, fair, and up-to-date with the latest law.